-
1 Comment
Active Biotech AB (publ) is currently in a long term downtrend where the price is trading 15.2% below its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 36.8.
Active Biotech AB (publ)'s total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 27.0% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 56.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Active Biotech AB (publ) gets an overall score of 3/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | SE0001137985 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Beta | 1.52 |
| Target Price | None |
| Market Cap | 26M |
| Dividend Yield | None |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BTPC.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
